Inflammatory and Mucociliary Dysfunction-Based Endotypes Across the Spectrum of Chronic Airway Diseases

It was already known that Chronic Obstructive Pulmonary Disease (COPD), asthma, Bronchiectasis (BE), and Cystic Fibrosis (CF) share overlapping clinical presentations. These respiratory conditions frequently exhibit persistent inflammation alongside impaired mucociliary clearance mechanisms. Traditional diagnostic frameworks rely heavily on clinical labels rather than underlying biological drivers. Such phenotypic classification often fails to account for the heterogeneous nature of airway pathology across different patient populations. Identifying specific molecular signatures could improve how clinicians categorize these complex respiratory ailments. Understanding the interplay between cellular signaling and physical mucus properties is essential for developing targeted therapies. This absence of evidence motivated the current investigation into whether biological markers can define more precise patient subgroups.

This research evaluates the intricate relationship between inflammatory signaling and mucociliary clearance across a broad spectrum of chronic respiratory conditions. The investigators sought to determine if biological endotypes provide a more accurate stratification than traditional disease labels. By analyzing sputum properties and microbial composition, the team aimed to identify therapeutically relevant subtypes. The study specifically examines whether distinct clusters emerge regardless of the primary clinical diagnosis. Researchers hypothesized that inflammatory markers and rheological parameters would reveal shared pathological pathways. This approach attempts to bridge the gap between symptomatic presentation and molecular reality in pulmonary medicine. The project also explores how microbial diversity and specific bacterial taxa correlate with these inflammatory signatures across the disease spectrum.

The investigative team recruited 76 individuals with asthma, 91 with COPD, 54 with BE, and 24 with CF, alongside 26 former smokers as controls. Participants provided spontaneous sputum samples for comprehensive biochemical and physical analysis. Laboratory technicians measured Neutrophil Elastase (NE) and 19 distinct cytokines, including Interferon-gamma (IFN-γ), Interleukin-4 (IL-4), and Interleukin-5 (IL-5), to characterize the local inflammatory environment. Physical properties including DNA content, mucin concentrations, dry weight, and rheological parameters were quantified. The researchers used long-read 16S Ribosomal Ribonucleic Acid (rRNA) sequencing to profile the sputum microbiome. K-means clustering algorithms then organized the data to identify natural groupings based on biological variables. Statistical comparisons evaluated differences both between established disease categories and within the newly identified clusters using a significance threshold of p<0.05.

K-means clustering successfully identified two primary biological signatures characterized by either neutrophilic or Type 2 Helper T-cell (Th2) inflammation. Nine specific cytokines, including Eotaxin, Eotaxin-3, Thymus and Activation-Regulated Chemokine (TARC), Granulocyte Colony-Stimulating Factor (G-CSF), Fractalkine, and Interleukin-22 (IL-22), showed significant variance across the study cohorts (p<0.05). The Th2-dominant cluster presented lower sputum dry weight and DNA content but significantly higher levels of Mucin 5B (MUC5B) relative to the neutrophilic group. Rheological measurements revealed that storage modulus (G'), loss modulus (G''), and complex modulus (G*) were elevated in the eosinophilic group compared to the neutrophilic cluster. Conversely, the neutrophilic cluster displayed a higher Tan(delta) value, indicating an increased viscous-to-elastic ratio in the mucus than that observed in the Th2 group. Microbiome analysis linked the neutrophilic endotype to decreased alpha diversity (p=0.04) and a higher prevalence of Proteobacteria in their sputum compared to the Th2 cluster (p=0.01). While neutrophilic inflammation predominated in 87% of CF and 78% of BE cases, it also appeared in 42% of COPD and 46% of asthma patients (p<0.0001).

The findings reveal that chronic airway diseases possess highly heterogeneous mucus properties that transcend traditional diagnostic boundaries. Patients naturally group according to their specific inflammatory endotype rather than their assigned clinical disease label. This biological stratification suggests that a one-size-fits-all approach to respiratory therapy may be insufficient. Utilizing inflammatory and mucociliary clearance biomarkers could significantly refine how clinicians assess and treat pulmonary conditions. Future research should investigate how these endotypes respond to targeted anti-inflammatory or mucoactive interventions. The study underscores the necessity of moving toward precision medicine in the management of chronic obstructive and restrictive lung diseases. These results provide a framework for developing more effective, biology-driven diagnostic protocols.